March 21st 2025
EsoBiotec’s proprietary lentiviral platform primarily enables the immune system to attack cancers but could ultimately offer patients cell therapy treatments delivered in minutes rather than several weeks.
The evolution of therapeutic modalities drives the adoption of single-use technologies.